Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q2 2016 · 10-Q
Revenue—
Net Income-$3.02M-$3.02MN/M vs Q2 2015 EPS Diluted-$0.46-$0.46N/M vs Q2 2015 Operating Income-$3,044,000N/M Operating Cash Flowderived-$3,274,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Jul 19, 2016 · 19 d after period end